# AMT-130

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/amt-130
Canonical HTML page: https://gethealthbrief.com/entity/amt-130

## Timeline

- **2026-06-30**: Type B FDA Meeting Target — Planned follow-up to define Phase III and regulatory path for AMT-130.
- **2026-06-30**: AMT-260 Data Readout — Expected clinical data from Phase I/IIa epilepsy study in H1 2026.
- **2026-03-02**: Type A FDA Meeting — Discussed AMT-130 approval pathway; alignment not yet reached.
- **2025-12-31**: Fiscal Year End — Closed 2025 with $622.5 million in liquidity.

## Recent coverage (3 stories)

### UniQure Surges 78% as FDA Greenlights BLA for Huntington's Gene Therapy AMT-130
2026-07-12 05:40:15 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

The FDA’s decision to accept existing AMT-130 clinical data for a BLA submission could fast-track the first disease-modifying treatment for Huntington’s disease, with major implications for healthcare systems, payers, and patients.
Full story: https://gethealthbrief.com/story/uniqure-surges-78-fda-huntingtons-gene-therapy-health

### 4 Biotech Movers Bring New Hope to Huntington’s, Cancer Patients
2026-06-19 00:09:33 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Clinical updates from uniQure, NTHI, and others signal tangible progress in gene therapy and oncology, offering potential new treatment options for patients with devastating diseases.
Full story: https://gethealthbrief.com/story/biotech-gainers-patient-hope

### uniQure Extends Cash Runway to 2029 Amid Ongoing FDA Talks for Huntington's
2026-03-03 00:53:41 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

uniQure reported a strong cash position of $622.5 million, extending its operational runway into 2029. While the company continues to seek regulatory alignment with the FDA for its Huntington’s disease candidate AMT-130, it is advancing clinical trials for epilepsy and Fabry disease with key data readouts expected in 2026.
Full story: https://gethealthbrief.com/story/uniqure-2025-financials-fda-huntingtons-update

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.